Surgical treatment of pancreatic endocrine neoplasms

Gomez-Rivera, Fernando; Stewart, Ashley; Arnoletti, J. Pablo; Vickers, Selwyn M.; Bland, Kirby I.; Heslin, Martin J.

doi:10.1016/j.amjsurg.2006.10.016

Cited by 22 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients with pancreatic NETs the 5-year RFS rate after correction for referral bias was 69%, the 5-year OS rate 90%. This is comparable with postoperative results reported in other series [7,14,24,25]. Median RFS tended to be longer in patients with midgut primary (98.8 months) compared to pancreatic primary (45.5 months, p = 0.16).…”

Section: Discussionsupporting

confidence: 81%

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

Dieckhoff¹,

Runkel²,

Daniel³

et al. 2014

Digestion

View full text Add to dashboard Cite

Background: Resection with curative intention is the cornerstone of treatment in patients with neuroendocrine tumors. A proportion of patients will relapse after R0 resection, but the factors predictive of recurrence are not well understood. Methods: A database established 1998 at the University Hospital Marburg was queried for all patients with documented R0 resection. Recurrence-free survival and overall survival were estimated using the Kaplan-Meier method. Uni- and multivariate analyses were performed. Results: 180 patients with a median age of 52 years entered the analysis. We observed 77 recurrences after a median time of 2.9 years. 24% of the recurrences occurred later than 5 years after operation. Median recurrence-free survival of the whole cohort was 101 months. In univariate analysis grade by Ki-67, stage, high lymph node ratio and microangioinvasion were significant predictors of recurrence. On multivariate analysis these parameters were confirmed as independent prognostic parameters with stage and microangioinvasion being the most important predictors. Conclusions: After R0 resection of neuroendocrine tumors, postoperative surveillance should be extended to at least 10 years. Patients with distant metastases and microangioinvasion are at high risk of recurrence. Clinical trials of adjuvant treatment protocols are indicated in these patients.

show abstract

Section: Discussionsupporting

confidence: 81%

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

Dieckhoff¹,

Runkel²,

Daniel³

et al. 2014

Digestion

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported median DFS durations of 88 months following resection of ileal NET (Landerholm et al 2011; Le Roux et al 2011) and 80–85 months following resection of panNET (Gomez-Rivera et al 2007; Boninsegna et al 2012). Our median DFS estimates of 70.1 months for patients with small bowel NET and 49.5 months for patients with panNET are somewhat shorter than these previous estimates.…”

Section: Discussionmentioning

confidence: 99%

“…We did not observe a strong association between lymph node involvement and shorter DFS in patients with panNET. Others have also failed to identify associations between lymph node involvement and DFS in panNET, and have suggested that lymph node ratio, rather than presence or absence of lymph nodes, may be a better prognostic measure for such patients (Gomez-Rivera et al 2007; Casadei et al 2010; Boninsegna et al 2012). …”

Section: Discussionmentioning

confidence: 99%

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database

Ter‐Minassian

Chan

Hooshmand

et al. 2013

Endocrine-Related Cancer

111

View full text Add to dashboard Cite

The rarity of neuroendocrine tumors (NET) has contributed to a paucity of large epidemiologic studies of patients with this condition. We characterized presenting symptoms and clinical outcomes in a prospective database of over 900 patients with NET. We used data from patient questionnaires and the medical record to characterize presenting symptoms, disease-free survival (DFS) and overall survival (OS). The majority of patients in this database had gastroenteropancreatic NET. The median duration of patient-reported symptoms prior to diagnosis was 3.4 months; 19.5% reported durations from 1 to 5 years, 2.5% from 5 to 10 years and 2% greater than 10 years. The median DFS among patients with resected small bowel NET or pancreatic NET was 5.8 yrs and 4.1 years, respectively. After correcting for left truncation bias, the median OS was 7.9 yrs for advanced small bowel NET and 3.9 yrs for advanced pancreatic NET. Chromogranin A (CGA) above twice the upper limit of normal was associated with shorter survival times (HR 2.8 (1.9, 4.0) p<0.001) patients with metastatic disease, regardless of tumor subtype. Our data suggest that while most NET patients are diagnosed soon after symptom onset, prolonged symptom duration prior to diagnosis is a prominent feature of this disease. Though limited to observations from a large referral center, our observations confirm the prognostic value of CGA, and suggest that median survival durations may be shorter than reported in other institutional databases.

show abstract

“…Other authors have reported prognostic factors predicting survival after the resection of PETs [7,8,9,10]. To our knowledge, prognostic factors related to the risk of recurrence in PETs have rarely been reported in the literature [11,12,13,14]. …”

Section: Introductionmentioning

confidence: 89%

“…However, the recurrence rate in these patients ranged from 24.5% [13] to 36.3% [14]; the median time of recurrence ranged from 6 [14] to 38 months [12] and the most frequent site of recurrence was the liver [11,12,13,14]. Bilimoria et al [7] reported the prognostic factors predicting survival after the resection of PETs described in the literature.…”

Section: Discussionmentioning

confidence: 99%

Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?

et al. 2010

View full text Add to dashboard Cite

Surgical treatment of pancreatic endocrine neoplasms

Cited by 22 publications

References 14 publications

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database

Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?

Contact Info

Product

Resources

About